Corporate Snapshot – Personalis Inc. (PSNL)
Current Trading Position At 12:52 AM Central Europe on Friday 23 Oct 2026, Personalis Inc. (NASDAQ: PSNL) closed down 0.25 %, trading at USD 15.82 per share. The stock’s 24‑hour volume amounted to USD 44.4 million, a modest figure relative to its market presence. Over the past month, the share price has declined 2.81 %, underscoring a period of consolidation amid broader market volatility.
Valuation Metrics
- Market Capitalisation: USD 1.70 billion
- Shares Outstanding: 106.6 million
- 200‑Day Simple Moving Average: USD 11.04
- 52‑Week Range: $4.96 (low, 29 Apr 2026) – $18.89 (high, 21 Aug 2026)
The current price sits comfortably above the 200‑day average, suggesting short‑term support. However, the 52‑week high remains a distant target, reflecting the company’s still‑maturing valuation trajectory.
Peer Landscape (Last 24 Hours)
| Symbol | Change | Current Price | Market Cap |
|---|---|---|---|
| BCRX | –2.39 % | USD 7.78 | USD 2.0 bn |
| SRPT | –3.18 % | USD 18.18 | USD 2.0 bn |
| XERS | –3.05 % | USD 10.86 | USD 2.0 bn |
| IMNM | +0.45 % | USD 18.26 | USD 2.0 bn |
| SGRY | –0.58 % | USD 15.93 | USD 2.0 bn |
Personalis’ decline is consistent with its peers, all of which occupy the mid‑$10s to $18 range. The slight outperformance of Immunome (IMNM) and the relative stability of Surgery (SGRY) hint at sector‑specific dynamics that may influence upcoming trade cycles.
Strategic Outlook Personalis remains a pivotal player in genomic sequencing and analytics, with a portfolio that supports personalized cancer vaccine development and next‑generation immunotherapies. The company’s global reach and deep technical expertise position it well to capitalize on the expanding precision‑medicine market.
While short‑term price action has been subdued, the firm’s underlying pipeline—particularly its contributions to oncology therapeutics—offers a robust growth engine. Investors should monitor upcoming data releases and regulatory milestones that could provide catalysts for a rebound.
Contact & Further Information For comprehensive details on Personalis’ products, research, and corporate governance, visit www.personalis.com . The company is listed on the Nasdaq exchange under the ticker PSNL.
